Future research may clarify the relationships between peripheral markers of inflammation, LRRK2 and brain inflammation and whether patients with PSP might benefit from LRKK2-lowering or cytokine-targeting therapies. The gene discussed is LRRK2; the disease is supranuclear palsy, progressive, 1.